Canada / The Evolution of Medical Cannabis Legislation
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its…
canada
Canada / Federal Consultations on a National Strategy for Rare Disease Drugs
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health Canada's consultation with Canadians on what a national strategy for high-cost rare disease…
Canada / Has the Time Truly Come for Trudeau’s ‘National Pharmacare’?
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs,…
Canada / Pharma News Roundup September 2020
The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt…
In Conversation
Brendan Kennedy – CEO, Tilray, Canada
Having just announced the first collaboration between a medical cannabis company and a major pharmaceutical player, Tilray expects to launch its first co-branded product with Sandoz Canada by the end of the year. Tilray’s founder and CEO Brendan Kennedy highlights the company’s main differentiation factors, including but not limited to its international reach through its presence in ten countries on…
Canada / Top 10 Pharma Companies 2020 Ranking
The Top 10 companies in the Canadian pharma market for 2020, ranked by revenues in USD billions. J&J takes the…
Related Report
Canada / COVID-19 Vaccination Strategies
Fasken Canada’s Dara Jospe and Denis Douville examine Canada’s COVID-19 vaccine strategy, from the…
Comprehensive Access to Medicines should be the Priority for National Pharmacare…
Canada is the only developed country with a universal healthcare system that does not provide universal coverage of…
Alzheimer's / Canadian-Led Innovation Post-Aducanumab
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for…
Canada: Smaller Market Entrants with Big Plans
Several smaller pharmaceutical companies – Taiho, Valneva, Mallinckrodt, Théa and Intercept Pharma –…
Canada / The Evolution of Medical Cannabis Legislation
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its…
Canada: science powering commerce
Despite declining investments by big pharma in recent years, Canada has created a number of innovative ways to…
A New Era in Access to Rare Disease Drugs in Canada
Durhane Wong-Rieger is the President & CEO of the Canadian Organization for Rare Disorders (CORD). In her first…
UK / New Post-Brexit Regulatory Alliance with Australia, Canada, Singapore & Switzerland
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to…
Canada / Collective Impact in the Health Charity Sector
Diabetes Canada’s Jan Hux outlines how her organization has been able to shift from small, local programs to…
Canada: Safeguarding Generics
With cost-cutting measures exacerbating an already fraught regulatory process, the Canadian generics industry is…
Canada / Global Pharma has Reinvented R&D: Will Canadian Start-Ups Lead the Next Phase?
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the…
Canada / Federal Consultations on a National Strategy for Rare Disease Drugs
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health…
Canada: Targeting Rare Diseases
The research areas in which Canada has the potential to excel are numerous, one being the world of genomics. The…
“Canada Needs to do Better in Supporting Innovative Biopharma”
Brian Hilberdink, President of Novo Nordisk Canada, calls for the Canadian government to encourage and invest in…